Şirket yükleniyor
LLYELI Lilly And Company$1,35TA+Just reported
From AbbVie's results release of 30 Ekim 2026; its quarterly report has since been filed.
Actual
$17,4B
+%10 y/y
+%2,4 q/q
Guided
—
No guide given
Actual
$2,37
+%17 q/q
Guided
—
No guide given
Actual
$6,27B
+%229 y/y
-%2,6 q/q
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Gelir payları fiscal year 2025, high confidence dönemi için tahmindir; resmî bir bildirimden alınmış rakamlar değildir.
Skyrizi
An injectable biologic medicine for autoimmune diseases including psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis. In 2026, U.S. and European regulators also approved it for some children with plaque psoriasis.
Rinvoq
A once-daily pill for several inflammatory and autoimmune diseases, including rheumatoid arthritis, atopic dermatitis, ulcerative colitis and Crohn's disease. European regulators approved it for vitiligo and severe alopecia areata in 2026.
Humira
An injectable biologic medicine used for autoimmune conditions including rheumatoid arthritis, psoriasis, Crohn's disease and ulcerative colitis. It faces competition from biosimilar medicines.
Botox Therapeutic and Botox Cosmetic
An injectable medicine used therapeutically for conditions including chronic migraine and muscle disorders; its cosmetic version temporarily reduces the appearance of facial lines.
Vraylar
A prescription medicine used to treat schizophrenia and episodes of bipolar disorder, and alongside other medicine for major depression.
Venclexta
A cancer medicine used for blood cancers including chronic lymphocytic leukemia and acute myeloid leukemia. In 2026, U.S. regulators approved a combination with another cancer medicine for some previously untreated adults with chronic lymphocytic leukemia.
AbbVie researches, tests, makes and sells prescription medicines and some medical devices. Its medicines treat immune diseases, neurological conditions, cancers, migraine, eye diseases and other conditions; it also sells cosmetic injections, fillers and skincare products. It sells mainly through wholesalers and distributors, with some aesthetic products sold directly to licensed health professionals.
AbbVie Inc. şirketinin ABD Menkul Kıymetler ve Borsa Komisyonu’na (SEC) sunduğu kendi belgelerinden kuruldu. Rakamlar bildirildiği gibidir; hisse başına geçmiş bugünkü hisse tabanına göre yeniden hesaplanmıştır. Bu bir işletmeyi anlatır — yatırım tavsiyesi değildir ve alma ya da satma önerisi değildir.
The themes AbbVie is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
$294,87+%0,311 Kas kapanış
30 Eylül 2026 tarihine kadarki rakamlar, 3 Kasım 2026 tarihinde sunulan 10-Q raporundan
AbbVie researches, develops and sells medicines and aesthetic treatments for immune diseases, neurological conditions, cancers and other health needs.
Grade B+
Fiyatın altındaki şerit, her tarihteki notu gösterir; yalnızca o tarihe kadar yayımlanmış belgelerden hesaplanır.
AbbVie Inc. şirketinin not geçmişinin 41 çeyreğinden 2 tanesi gösteriliyor. Diğer 39 çeyrek Kasım 2016 tarihine kadar uzanıyor.
